H. Brodaty, K. Seeher, and L. Gibson, Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia, Int Psychogeriatr, vol.24, pp.1034-1079, 2012.

S. Todd, S. Barr, M. Roberts, and A. P. Passmore, Survival in dementia and predictors of mortality: a review, Int J Geriatr Psychiatry, vol.28, pp.1109-1133, 2013.

S. E. Tom, R. A. Hubbard, P. K. Crane, S. J. Haneuse, J. Bowen et al., Characterization of dementia and Alzheimer's disease in an older population: updated incidence and life expectancy with and without dementia, Am J Public Health, vol.105, pp.408-421, 2015.

, Alzheimer's disease facts and figures, Alzheimers Dement, vol.12, pp.459-509, 2016.

B. D. James, S. E. Leurgans, L. E. Hebert, P. A. Scherr, K. Yaffe et al., Contribution of Alzheimer disease to mortality in the United States, Neurology, vol.82, pp.1045-50, 2014.

C. A. Taylor, S. F. Greenlund, L. C. Mcguire, H. Lu, and J. B. Croft, Deaths from Alzheimer's disease -United States, MMWR Morb Mortal Wkly Rep, vol.66, pp.521-527, 1999.

G. Lewis, N. Werbeloff, J. F. Hayes, R. Howard, and D. Osborn, Diagnosed depression and sociodemographic factors as predictors of mortality in patients with dementia, Br J Psychiatry, vol.213, pp.471-477, 2018.

I. E. Van-de-vorst, H. L. Koek, R. De-vries, M. L. Bots, J. B. Reitsma et al., Effect of vascular risk factors and diseases on mortality in individuals with dementia: a systematic review and meta-analysis, J Am Geriatr Soc, vol.64, pp.37-46, 2016.

T. G. Beach, S. E. Monsell, L. E. Phillips, and W. Kukull, Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, J Neuropathol Exp Neurol, vol.71, pp.266-73, 2005.

K. Blennow and H. Zetterberg, Biomarkers for Alzheimer's disease: current status and prospects for the future, J Intern Med, vol.284, pp.643-63, 2018.

G. M. Mckhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.263-272, 2011.

B. Dubois, H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, pp.614-643, 2014.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease, Alzheimers Dement, vol.14, pp.535-62, 2018.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, H. H. Feldman et al., A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-586, 2016.

C. Paquet, E. Bouaziz-amar, E. Cognat, L. Volpe-gillot, V. Haddad et al., Distribution of cerebrospinal fluid biomarker profiles in patients explored for cognitive disorders, J Alzheimers Dis, vol.64, pp.889-97, 2018.

J. Dumurgier, O. Vercruysse, C. Paquet, S. Bombois, C. Chaulet et al., Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting, Alzheimers Dement, vol.9, pp.406-419, 2013.

J. Dumurgier, S. Schraen, A. Gabelle, O. Vercruysse, S. Bombois et al., Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: a multicentric study, Alzheimers Res Ther, vol.7, p.30, 2015.

N. Mattsson, U. Andreasson, S. Persson, M. C. Carrillo, S. Collins et al., CSF biomarker variability in the Alzheimer's Association quality control program, Alzheimers Dement, vol.9, pp.251-61, 2013.

J. Dumurgier, J. L. Laplanche, F. Mouton-liger, P. Lapalus, S. Indart et al., The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials, J Neurol, vol.261, pp.1187-95, 2014.

M. Degerman-gunnarsson, L. Lannfelt, M. Ingelsson, H. Basun, and L. Kilander, High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease, Dement Geriatr Cogn Disord, vol.37, pp.196-206, 2014.

H. Rhodius-meester, H. Liedes, T. Koene, A. W. Lemstra, C. E. Teunissen et al., Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease, Alzheimers Res Ther, vol.10, p.23, 2018.

A. H. Shadyab and A. Z. Lacroix, Genetic factors associated with longevity: a review of recent findings, Ageing Res Rev, vol.19, pp.1-7, 2015.

T. Skillback, R. Lautner, N. Mattsson, J. M. Schott, I. Skoog et al., Apolipoprotein E genotypes and longevity across dementia disorders, Alzheimers Dement, vol.14, pp.895-901, 2018.

O. L. Lopez, J. T. Becker, Y. Chang, W. E. Klunk, C. Mathis et al., Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality, Neurology, vol.90, pp.1920-1928, 2018.

T. Tapiola, I. Alafuzoff, S. K. Herukka, L. Parkkinen, P. Hartikainen et al., Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch Neurol, vol.66, pp.382-391, 2009.

T. T. Seppala, O. Nerg, A. M. Koivisto, J. Rummukainen, L. Puli et al., CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, vol.78, pp.1568-75, 2012.

S. M. Landau, M. Lu, A. D. Joshi, M. Pontecorvo, M. A. Mintun et al., Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid, Ann Neurol, vol.74, pp.826-862, 2013.

S. Palmqvist, H. Zetterberg, N. Mattsson, P. Johansson, L. Minthon et al., Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease, Neurology, vol.85, pp.1240-1249, 2015.

I. Casserly and E. Topol, Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins, Lancet, vol.363, pp.1139-1185, 2004.

J. Attems and K. A. Jellinger, The overlap between vascular disease and Alzheimer's disease--lessons from pathology, BMC Med, vol.12, p.206, 2014.

L. V. D'uscio, T. He, and Z. S. Katusic, Expression and processing of amyloid precursor protein in vascular endothelium, Physiology (Bethesda), vol.32, pp.20-32, 2017.

D. M. Jans, W. Martinet, T. J. Van-de-parre, A. G. Herman, H. Bult et al., Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease, Cardiovasc Hematol Disord Drug Targets, vol.6, pp.21-34, 2006.

A. Gabelle, S. Schraen, L. A. Gutierrez, C. Pays, O. Rouaud et al., Plasma beta-amyloid 40 levels are positively associated with mortality risks in the elderly, Alzheimers Dement, vol.11, pp.672-80, 2015.

K. Stamatelopoulos, D. Sibbing, L. S. Rallidis, G. Georgiopoulos, D. Stakos et al., Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease, J Am Coll Cardiol, vol.65, pp.904-920, 2015.

J. Cummings, G. Lee, A. Ritter, and K. Zhong, Alzheimer's disease drug development pipeline, Alzheimers Dement (N Y), vol.4, pp.195-214, 2018.

L. S. Honig, B. Vellas, M. Woodward, M. Boada, R. Bullock et al., Trial of solanezumab for mild dementia due to Alzheimer's disease, N Engl J Med, vol.378, pp.321-351, 2018.